Drug Profile
Research programme: diabetes/obesity therapy - Dainippon Sumitomo Pharma/Zoegene
Alternative Names: Diabetes/obesity therapy research programme - Dainippon/ZoegeneLatest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma; Zoegene Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 08 Feb 2008 Discontinued for Diabetes mellitus in Japan (unspecified route)
- 08 Feb 2008 Discontinued for Obesity in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma